See more : Synthetic Biologics, Inc. (SYN) Income Statement Analysis – Financial Results
Complete financial analysis of MPX International Corporation (MPXOF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MPX International Corporation, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Daiwa Securities Group Inc. (8601.T) Income Statement Analysis – Financial Results
- Foosung Co., Ltd. (093370.KS) Income Statement Analysis – Financial Results
- QuantumScape Corporation (QS) Income Statement Analysis – Financial Results
- Caisse Régionale de Crédit Agricole Mutuel du Languedoc Société coopérative (CRLA.PA) Income Statement Analysis – Financial Results
- Rex Resources Corp. (OWN.V) Income Statement Analysis – Financial Results
MPX International Corporation (MPXOF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://mpxinternationalcorp.com
About MPX International Corporation
MPX International Corporation, a cannabis company, focuses on the medical and adult-use cannabis markets in Canada and Switzerland. It is involved in producing and distributing three types of products, such as cannabis flowers, cannabis extract and related products, and cannabis derivatives under the Strain Rec and Salus BioPharma brands. The company was founded in 2015 and is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 7.21M | 3.17M | 1.59M | 64.45K |
| Cost of Revenue | 0.00 | 0.00 | 2.68M | 8.55B | 4.59B | 23.21K |
| Gross Profit | 0.00 | 0.00 | 4.53M | -8.55B | -4.58B | 41.24K |
| Gross Profit Ratio | 0.00% | 0.00% | 62.88% | -269,637.23% | -288,039.71% | 63.99% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 12.63M | 13.19M | 11.36M | 1.35M |
| Selling & Marketing | 0.00 | 0.00 | 372.30K | 450.08K | 948.18K | 108.56K |
| SG&A | 0.00 | 0.00 | 13.00M | 13.64M | 12.31M | 1.46M |
| Other Expenses | 0.00 | 0.00 | -528.61K | -690.98K | 1.65M | 0.00 |
| Operating Expenses | 0.00 | 0.00 | 18.57M | 18.46M | 15.34M | 2.13M |
| Cost & Expenses | 0.00 | 0.00 | 21.25M | 16.99M | 10.49M | 2.15M |
| Interest Income | 0.00 | 0.00 | 8.00 | 13.77K | 26.74K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 4.32M | 885.49K | 303.88K | 189.00 |
| Depreciation & Amortization | 167.90K | 228.49K | 6.07M | 4.78M | 2.84M | 597.32K |
| EBITDA | 0.00 | 0.00 | -16.01M | -9.76M | -6.16M | -1.51M |
| EBITDA Ratio | 0.00% | 0.00% | -110.48% | -307.65% | -386.76% | -2,375.70% |
| Operating Income | 0.00 | 0.00 | -14.56M | -16.03M | -8.89M | -2.08M |
| Operating Income Ratio | 0.00% | 0.00% | -201.96% | -505.51% | -558.82% | -3,234.78% |
| Total Other Income/Expenses | 0.00 | 0.00 | -11.84M | -25.70M | -226.66K | -20.35K |
| Income Before Tax | 0.00 | 0.00 | -26.40M | -41.73M | -9.12M | -2.11M |
| Income Before Tax Ratio | 0.00% | 0.00% | -366.16% | -1,315.85% | -573.06% | -3,266.35% |
| Income Tax Expense | 0.00 | 0.00 | 231.75K | -686.91K | 258.00K | -43.44K |
| Net Income | 0.00 | 0.00 | -26.63M | -41.05M | -9.38M | -2.11M |
| Net Income Ratio | 0.00% | 0.00% | -369.38% | -1,294.20% | -589.27% | -3,266.35% |
| EPS | 0.00 | 0.00 | -0.19 | -0.29 | -0.13 | -0.05 |
| EPS Diluted | 0.00 | 0.00 | -0.19 | -0.29 | -0.13 | -0.05 |
| Weighted Avg Shares Out | 0.00 | 0.00 | 143.02M | 140.06M | 71.69M | 45.30M |
| Weighted Avg Shares Out (Dil) | 0.00 | 0.00 | 143.02M | 140.06M | 71.69M | 45.30M |
Source: https://incomestatements.info
Category: Stock Reports